第一医药(600833) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 20.91% to CNY 29,206,820.88 for the first nine months of the year[5] - Operating revenue for the first nine months decreased by 27.04% to CNY 858,732,420.94 compared to the same period last year[5] - Total profit for the first nine months of 2018 was ¥37,375,309.90, a decrease of 21.5% compared to ¥47,636,728.37 in the same period of 2017[17] - Net profit for the first nine months of 2018 was CNY 27.92 million, down 19.0% from CNY 34.46 million in the same period last year[18] - The company reported a decrease in total profit for the first nine months of 2018 to CNY 32.00 million, down 22.9% from CNY 41.48 million in the same period last year[18] Assets and Liabilities - Total assets decreased by 3.28% to CNY 1,098,743,429.37 compared to the end of the previous year[5] - The company's total liabilities increased to RMB 437,193,905.93 from RMB 421,903,306.42, representing a rise of about 3.1%[14] - The total equity attributable to shareholders decreased from RMB 707,057,559.56 to RMB 654,542,207.55, indicating a decline of approximately 7.4%[14] - Accounts receivable decreased by 32.96% to CNY 98,971,234.87 compared to the beginning of the year[9] - Current liabilities totaled RMB 380,489,792.04, up from RMB 341,871,920.65, which is an increase of approximately 11.3%[14] Cash Flow - Cash flow from operating activities increased by 21.51% to CNY 81,380,761.18 for the first nine months[5] - Cash flow from operating activities for the first nine months of 2018 was CNY 81.38 million, an increase of 21.5% compared to CNY 66.97 million in the previous year[20] - The company’s cash flow from operating activities remains strong despite a slight decline in total cash inflow[21] - Total cash inflow from operating activities was CNY 537,250,790.54, a decrease of 3.0% from CNY 553,811,788.09 year-on-year[21] Income and Expenses - The company reported a significant increase in other income by 101.74% to CNY 3,657,141.53 for the first nine months[9] - Sales expenses increased to CNY 33.41 million for the first nine months of 2018, up 17.5% from CNY 28.55 million in the same period last year[18] - Total operating costs for the first nine months of 2018 were ¥830,576,383.51, a decrease of 26.9% from ¥1,136,070,660.52 in the same period of 2017[17] Shareholder Information - The total number of shareholders reached 25,033 by the end of the reporting period[8] Cash and Cash Equivalents - Cash and cash equivalents increased to RMB 389,523,115.41 from RMB 323,804,685.79, marking a growth of about 20.3%[13] - Cash and cash equivalents at the end of Q3 2018 were CNY 389.22 million, an increase of 37.8% from CNY 282.24 million at the end of Q3 2017[20] - Cash and cash equivalents at the end of the period totaled CNY 362,841,340.29, up 45.6% from CNY 249,223,894.65 at the end of the same period last year[21] Investment Activities - Investment activities resulted in a net cash outflow of CNY 2.28 million for the first nine months of 2018, compared to a net inflow of CNY 3.33 million in the previous year[20] - Investment activities generated a net cash flow of CNY 19,426,291.77, an increase of 55.0% compared to CNY 12,551,327.62 last year[21] - The company received CNY 24,387,413.96 in investment income, an increase of 86.0% compared to CNY 13,076,738.59 last year[21]